Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Coya Therapeutics, Inc. (NASDAQ:COYA) has received a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $15.3333.

A number of analysts have recently issued reports on COYA shares. Roth Mkm started coverage on Coya Therapeutics in a research note on Friday. They issued a “buy” rating and a $12.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, March 23rd. Wall Street Zen lowered Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. D. Boral Capital reissued a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a research note on Friday, April 10th. Finally, Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 16th.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. acquired a new position in Coya Therapeutics during the third quarter worth $28,000. CIBC Private Wealth Group LLC acquired a new position in Coya Therapeutics during the fourth quarter worth $47,000. Occudo Quantitative Strategies LP acquired a new position in Coya Therapeutics during the fourth quarter worth $66,000. Lantern Wealth Advisors LLC acquired a new position in Coya Therapeutics during the third quarter worth $66,000. Finally, Oppenheimer & Co. Inc. acquired a new position in Coya Therapeutics during the fourth quarter worth $81,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Trading Down 9.2%

Shares of COYA stock opened at $4.42 on Friday. The stock has a 50 day moving average of $4.45 and a 200 day moving average of $4.90. The stock has a market cap of $103.69 million, a P/E ratio of -3.84 and a beta of 0.62. Coya Therapeutics has a twelve month low of $3.71 and a twelve month high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. The business had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. On average, research analysts predict that Coya Therapeutics will post -1.5 earnings per share for the current fiscal year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.